News

With the help of NGS, new research is emerging for targeted therapies of rare mutations in lung cancer.

Precision medicine is sweeping across the cancer care spectrum, and now, experts have their sights set on applying it in MCL.

Steps in orthopedic oncology are being made after the first-ever global perspective trial in its field completed patient accrual.

Several late-stage therapies, including targeted agents and immunotherapies, are being evaluated for patients with relapsed/refractory colorectal cancer (CRC) who have progressed on first- and second-line therapies.

New study results show that chemoimmunotherapy combination options provide an overall survival benefit to patients with stage IV nonsquamous NSCLC.

The FDA has approved the biosimilar pegfilgrastim for treatment to decrease the incidence of infection exhibited from febrile neutropenia.

Wnt emerges as an exciting and favorable pathway for the treatment of patients with CRC.

President Trump has announced he will be nominating Stephen M. Hahn, MD, FASTRO, to be the next commissioner of the FDA.

Patients with cancer are faced with chronic pain that nurses often cannot manage properly due to outdated restrictions and practices.

Any patient with cancer needs a caregiver through the treatment journey, but it's even more vital for patients with cancer undergoing the stem cell transplant process.

The FDA has granted an RMAT designation for an investigational CAR-T cell therapy used to treat patients with multiple myeloma.

Here are the top 5 Oncology Nursing News® stories for October 2019.

Frahad Ravandi-Kashani, MD, had the chance to discuss the role of MRD in treating patients with hairy cell leukemia.

New therapeutic options are emerging for patients with Lung cancer positive for ALK or ROS1.

The NDA for Blueprint Medicines' agent avapritinib will be split into two separate submissions for patients with GIST.

An update to the biologics license application of eflapegrastim has been resubmitted to the FDA to include chemo-induced neutropenia.

Following concerns over breast implant-associated cancer and illnesses, the Food and Drug Administration issued draft guidelines for additional labeling measures on devices.

Results from the phase III CARD trial suggest positive outcomes for patients with advanced prostate cancer on a novel treatment chemotherapy combination therapy treatment.

At the 2019 ESMO Congress, the phase II KATE2 trial missed its primary endpoint but found promising results for a subgroup of patients with HER2-positive breast cancer with a PD-L1 expression.

The FDA approves the use of niraparib in the treatment of patients with HRD-positive advanced ovarian cancer based on results from the phase II QUADRA study.

The FDA has expanded the approval of aprepitant to include in its label the use of a single dose regimen in patients receiving moderately epigenetic chemotherapy.

Immunotherapy is sometimes considered solely for the later stages of treatment, but findings from a new study show promise for immunotherapy in treating patients with early breast cancer.

ACCC is celebrating the 15th anniversary of Oncology Pharmacy Education Network by honoring its founders.

Stress management is vital for any profession, but for oncology nurses, stress management is crucial to not only helping themselves but also helping their patients.

Looking at biomarkers PD-L1 and TMB in tandem can help predict a patient with NSCLC reaction to immunotherapy.

A label update from the FDA has approved a sBLA for romiplostim to include data demonstrating sustained platelet responses in adults with ITP.

By implementing a survivorship program at their cancer center, oncology nurses were able to improve the quality of life in patients with recurrent breast cancer.

The FDA has granted a priority review for Trastuzumab Deruxtecan to treat HER2-positive metastatic breast cancer based on the results from two new studies.

At the 2019 ESMO Congress, results for the MONALEESA-3 trial showed promise for patients with breast cancer and had many experts excited over its clinical implications.

In this month’s episode of CURE Talks Cancer Podcast: Nursing Edition, we had the chance to speak with Chasity M. Washington, MPH, CHES, on how the diversity in the workplace is important to cancer care.